Soon we’ll not be supporting this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Immunovant Inc (IMVT) USD0.0001

Sell:$8.98 Buy:$8.99 Change: $0.32 (3.70%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Sell:$8.98
Buy:$8.99
Change: $0.32 (3.70%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
Sell:$8.98
Buy:$8.99
Change: $0.32 (3.70%)
Market closed |  Prices as at close on 27 September 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Immunovant, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients with autoimmune diseases. The Company is developing IMVT-1401, a human anti-FcRn monoclonal antibody, as a subcutaneous injection for the treatment of autoimmune diseases mediated by pathogenic IgG antibodies. IMVT-1401 is being developed to target the neonatal Fc receptor (FcRn). It is also developing IMVT-1401 as a fixed-dose subcutaneous injection and focused initial development on the treatment of myasthenia gravis (MG), warm autoimmune hemolytic anemia (WAIHA), and thyroid eye disease (TED).

Contact details

Address:
320 West 37Th Street
NEW YORK
10018
United States
Telephone:
+1 (917) 5803099
Website:
https://immunovant.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
IMVT
ISIN:
US45258J1025
Market cap:
$994.74 million
Shares in issue:
115.00 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Frank Torti
    Executive Chairman of the Board
  • Peter Salzmann
    Chief Executive Officer, Director
  • Renee Barnett
    Chief Financial Officer
  • Julia Butchko
    Chief Development and Technology Officer
  • William Macias
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.